Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 41

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
6 417 (411)29 631 (602)Salaries and benefits related costs292 448 (156)622 842 (220)Consulting & Other44 14 30 62 79 (17)Stock-based compensation263 217 46 423 783 (360)Total research and development expenses$1,541 $3,563 $(2,022)$3,730 $6,378 $(2,648)

Three Months Ended June 30,Six Months Ended June 30,20252024Change20252024ChangeGeneral and administrative expenses:Salaries and benefits related costs$234 $300 $(66)$464 $624 $(160)Legal fees74 175 (101)242 433 (191)Audit fees88 58 30 165 173 (8)Consulting121 167 (46)317 339 (22)Insurance160 275 (115)316 561 (245)Other106 157 (51)209 341 (132)Stock-based compensation381 374 7 656 963 (307)Total general and administrative expenses$1,164 $1,506 $(342)$2,369 $3,434 $(1,065)

Three Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2024

Research and development expenses during the three months ended June 30, 2025 decreased $2.0 million or 57%, compared to the three months ended June 30, 2024, and were primarily due to the following:

•Salaries and benefits related costs decreased $0.2 million as we did not accrue current year bonus accruals due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur.  

•Clinical trial expenses decreased $1.5 million primarily due to lower INVINCIBLE-3 Study costs.  In March 2025, we paused new site activations and patient enrollments in the INVINCIBLE-3 Study, due to funding constraints. Prior to this pause, the trial had enrolled 23 patients.  We will continue to treat all patients enrolled in this study in cooperation with our third-party contract research organizations during this pause, and once sufficient funding is obtained, we plan to restart site activations and patient enrollment.  

18

•Contract manufacturing costs declined by $0